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eukaryotic translation initiation factor 4E, and
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Background: Pim-1 kinase is a proto-oncogene and its dysregulation contributes to tumorigenesis and progression
of a variety of malignancies. Pim-1 was suggested as a therapeutic target of cancers. The functional relevance of
Pim-1 and the mechanism underlying its dysregulation in lung tumorigenesis remained unclear. This study aimed
to investigate if Pim-1 has important functions in non-small-cell lung cancer (NSCLC) by: 1) evaluating the
clinicopathologic significance of Pim-1 through analysing its expression in 101 human NSCLCs tissues using quantitative
PCR, Western Blot and immunohistochemical studies, 2) determining its role in NSCLC and drug resistance using
in vitro assays, and 3) investigating the regulatory mechanism of Pim-1 dysregulation in lung tumorigenesis.
Results: Pim-1 was upregulated in 66.2% of the lung tumor tissues and its expression was significantly related to
advanced stage (P = 0.019) and lymph node metastasis (P = 0.026). Reduced Pim-1 expression suppressed NSCLC cell
growth, cell cycle progression and migration in vitro. Pim-1 was a novel target of miR-486-5p determined by luciferase
report assay, and ectopic miR-486-5p expression in cancer cells reduced Pim-1 expression. Furthermore, eukaryotic
translation initiation factor 4E (eIF4E) controlled the synthesis of Pim-1 in NSCLC cells, and its expression was positively
associated with that of Pim-1 in NSCLC tissue specimens (r = 0.504, p < 0.001). The downregulated miR-486-5p and
upregulated eIF4E in NSCLC cells led to the overexpression of Pim-1 by relieving the inhibitory effect of the 3′-UTR or
5′-UTR of Pim-1 mRNA, respectively. Moreover, Pim-1 knockdown sensitized NSCLC cells to cisplatin and EGFR tyrosine
kinase inhibitor, gefitinib.
Conclusions: Pim-1 kinase could be a critical survival signaling factor in NSCLC, and regulated by miR-486-5p and eIF4E.
Pim-1 kinase may provide a potential target for diagnosis and treatment for lung cancer.Background
Pim-1 belongs to the active serine/threonine kinase family.
It functions as a proto-oncogene whose activation could
promote the development of cancer in animal models
[1,2]. Several target proteins of Pim-1 are involved in
apoptosis, cell cycle regulation, signal transduction path-
ways and transcriptional regulation, which are linked to
cell survival. Thus, overexpression of Pim-1 in cancer cells
can substantially contribute to malignant transformation,
tumor progression and poor prognosis [3]. Elevated levels* Correspondence: xinglingxiao@hotmail.com
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unless otherwise stated.of Pim-1 have been found in human hematological malig-
nancies [4] and certain solid cancers, including prostate
cancer [5], head and neck squamous cell carcinomas [6],
colon carcinoma [7], and pancreatic ductal adenocarcin-
oma [8]. Furthermore, targeting Pim-1 sensitized prostate
and colon cancer cells to chemotherapeutic agents
[7,9,10], and improved the efficacy of AKT inhibitors and
epidermal growth factor receptor (EGFR) targeted therap-
ies in prostate cancer [11,12]. Therefore, targeting Pim-1
may provide a new therapeutic approach for the cancers.
Lung cancer is the leading cause of cancer death,
mainly due to the lack of effective treatment and the de-
velopment of resistance to chemotherapeutic agents. The
development of effective therapeutics for lung cancer is
urgently needed. Pim-1 expression at mRNA and proteind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ported in few study, however the results were controver-
sial. Warnecke et al. [13] reported that Pim-1 expressions
at mRNA and protein levels were significantly decreased
in NSCLC tissues compared to normal lung tissues. How-
ever, Nasser et al. [14] indicated that Pim-1 expression at
mRNA level was considerably elevated in NSCLC tissues
compared to the paired normal lung tissues. Jin et al. [15]
recently found that Pim-1 protein expression correlated
with advanced clinical stage and lymph node metastasis of
patients using immunohistochemical assays. Until now,
the functions of Pim-1 in the development and progres-
sion as well as the mechanism underlying its dysregulation
in tumorigenesis of NSCLC are still uncertain.
It has been well established that microRNAs (miR-
NAs) play important gene-regulatory roles by pairing to
the 3′-UTR of specific target mRNAs [16]. MiRNAs can
posttranscriptionally regulate the expression of hundreds
of their target genes, thereby controlling a wide range of
biological processes. Pim-1 has been found to be nega-
tively regulated by some miRNAs, such as miR-15 [7],
miR-1 [15], miR-328 [17], miR-33a [18] and miR-210
[19]. Previously, we have identified a set of 26 miRNAs
whose abnormal expressions are associated with human
NSCLC. Among the 26 miRNAs, miR-486-5p is one of
the most downregulated miRNAs in lung tumor tissues.
We have found that miR-486-5p is a valuable diagnostic
biomarker for early detection of NSCLC in sputum and
plasma [20-22]. We also demonstrated that miR-486-5p
acted as a tumor-suppressor in the development and
progression of NSCLC through targeting ARHGAP5
[23]. To further identify additional novel targets of miR-
486-5p that may play an important function in the de-
velopment and progression of NSCLC, we predict its
targeted genes using bioinformatic assays. Interestingly,
Pim-1 was the top 25 high-scoring candidates among
the 32853 genes predicted by miRecords (http://mirecords.
biolead.org/). This observation led us to explore the
underlying mechanism of miR-486-5p on the expression
of Pim-1 in NSCLC.
Eukaryotic translation initiation factor 4E (eIF4E), the
component of eIF4F translation initiation complex, is
the least abundant of the initiation factor. EIF4E is con-
sidered as the rate-limiting component for initiation of
cap-dependent translation [24]. EIF4E overexpression
can cause preferential translation of mRNAs containing
excessive secondary structure in their 5′-UTR that are
normally inefficiently translated, like growth promoting
protein and oncogenic proteins MYC, CCND1 and
VEGF. By this mechanism, eIF4E overexpression in can-
cer cells is associated with cancer-related events such
as transformation, angiogenesis, invasion and metastasis
[25]. Pim-1 has a 400-nucleotide long, 76% G/C-rich
and highly structured 5′-UTR in its mRNA, which hasthe potential to inhibit translation under normal cellular
conditions [26]. However, whether eIF4E is involved in
the regulation of Pim-1 expression and tumorigenesis of
NSCLC remained uncertain.
In the study, we aimed to evaluate the roles of Pim-1
kinase in tumorigenesis and drug resistance of NSCLC,
and to explore the possible mechanism underlying Pim-
1 dysregulation in lung carcinogenesis by: evaluating the
clinicopathologic significance of Pim-1 through analys-
ing the expression in 101 human NSCLCs tissues using
quantitative PCR, Western Blot and immunohistochemi-
cal studies, determining its role in NSCLC and drug re-
sistance using in vitro assays, and investigating the
regulatory mechanism of miR-486-5p and eIF4E on
Pim-1 expression in lung tumorigenesis.
Results
Pim-1 protein is frequently overexpressed in human NSCLC
To evaluate clinical significance of Pim-1 expression, we
performed immunohistochemical studies on formalin-
fixed and paraffin-embedded (FFPE) sections of 77 NSCLC.
Pim-1 staining was detected in the nucleus and cytoplasm
of carcinoma cells (Figure 1A). Positive staining of Pim-1
was found in 66.2% (51/77) of NSCLC tissues (Table 1),
but only 14.3% (3/21) in normal lung tissues. Furthermore,
Pim-1 expression was significantly higher in NSCLC tis-
sues than in adjacent normal tissues (P < 0.001). In
addition, Pim-1 expression in NSCLC tissues was signifi-
cantly associated with tumor size (P = 0.002), lymph node
metastasis (P = 0.026), histological type (P < 0.001) and
clinical staging (P = 0.019) in NSCLC patients (Table 1).
Therefore, upregualtion of Pim-1 was associated with ag-
gressive behaviour of lung cancer. Analysis of expression
level of the gene may help predict outcome of NSCLC.
We further compared Pim-1 expression in matched pairs
of frozen tumor and normal tissues from 24 NSCLC pa-
tients by using qRT-PCR and Western Blot assays. At
mRNA level, Pim-1 was upregulated only in 37.5% (9/24)
tumor tissues when compared with the paired normal lung
tissues. Furthermore, there was no significant difference
in the average level of Pim-1 mRNA between tumor
and paired normal lung tissues (Figure 1B, P > 0.05). In
contrast, at protein level, Pim-1 expression was overex-
pressed in 87.5% (21 of 24) tumor tissues than in adjacent
normal tissues (Figure 1C and Additional file 1: Table S1).
Wilcoxon matched pair rank test further demonstrated that
Pim-1 protein expression in tumors was statistically higher
than that in normal tissues (Z = −4.257, P < 0.001). Collec-
tively, Pim-1 protein is frequently overexpressed in NSCLC.
Knockdown Pim-1 inhibits cell growth, cell cycle
progression and migration of NSCLC cells in vitro
To explore the functions of Pim-1 in lung tumorigenesis,
we used specific siRNA against Pim-1 (si-Pim-1) to
Figure 1 Pim-1 protein is frequently overexpressed in human NSCLC. (A) Pim-1 expression was detected by immunohistochemistry analysis
with Pim-1 antibody in normal lung tissue (a-b), squamous cell carcinoma (c-d), and adenocarcinoma (e-f) of lung. (c and e): Pim-1 expression
mainly seen in cytoplasm of carcinoma cells, SP, 20 × 10; (d and f): Pim-1 expression in nucleus of carcinoma cells prominently, SP, 40 × 10.
(B) The level of Pim-1 mRNA in 24 cases of human NSCLC and matched normal lung tissues by qRT-PCR assay. (C) Pim-1 protein expression in
tumor tissues (T) and paired normal lung tissues (N) from the same sets as in (B) by Western blot assay.
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Table 1 Clinicopathologic characteristics of the NSCLC






All cases 77 51 26
Age (y) 0.807
<=60 37 24 13
>60 40 27 13
Gender
Male 53 37 16 0.324
Female 24 14 10
Histology <0.001
Squamous cell carcinoma 28 24 4
Adenocarcinoma 44 27 17
Other types 5 0 5
Tumor size 0.002
<=3 cm 43 22 21
>3 cm 34 29 5
Lymphnodemetastasis 0.026
Negative 31 16 15
Positive 46 35 11
Metastasis
No 51 28 23 0.003
Yes 26 23 3
Stage
I 23 13 10 0.019
II 18 11 7
III 10 4 6
IV 26 23 3
NOTE: P values <0.05 were considered statistically significant.
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ful knockdown of Pim-1 was confirmed by qRT-PCR
and Western Blot assays (Figure 2A). Cell growth was
significantly suppressed in cells transfected with si-Pim-
1 compared with the control cells at 48 h, 72 h and 96 h
after transfection by MTT assay (P < 0.05, Figure 2B).
The antiproliferative effect of the siRNA-mediated Pim-
1 knockdown was also confirmed in clone formation
assay in A549 cells (Additional file 2: Figure S1). Fur-
thermore, Flow Cytometry (FCM) results indicated that
the proportion of cells in G0/G1 phase was increased sig-
nificantly, whereas cells in S phase was significantly de-
creased in si-Pim-1 transfected cells compared to the
control (P <0.05, Figure 2C). Cyclin D1 and CDK4 pro-
teins (the key proteins in controlling the cell cycle tran-
sition from G1 to S phase) were assessed by Western
Blot. As shown in Figure 2D, the levels of Cyclin D1 andCDK4 protein were considerably decreased in si-Pim-1
transfected cells, further indicating that Pim-1 downreg-
ulation led cells to be arrested at G0/G1 phase.
Monolayer wound healing assay was performed to
observe the role of si-Pim-1 transfection in A549 and
H1299 cells. As shown in Figure 3A, the speed which
cells migrated towards the scratch was lower in si-Pim-1
transfected cells when compared with the control ones.
Transwell assay in A549 cells further indicated that loss
of Pim-1 considerably suppressed the migratory ability
of the NSCLC cells (Figure 3B and C). Taken together,
the observations suggest that Pim-1 might have onco-
genic functions in NSCLC.
Pim-1 expression is negatively regulated by miR-486-5p
at posttranscriptional level in NSCLC
We have previously shown that miR-486-5p may act as a
tumor suppressor whose downregulation could contrib-
ute to progression and metastasis of NSCLC [23]. To
further elucidate the mechanisms responsible for the
tumor-suppressive abilities of miR-486-5p, we use bio-
informatic analysis to identify additional novel targets
of miR-486-5p. Interestingly, miR-486-5p was the top
ten miRNAs that bind to the 3′-UTR region of Pim-1
(miRecords: http://mirecords.biolead.org/).
To determine whether Pim-1 could be regulated by
miR-486-5p, we performed luciferase reporter assay. The
luciferase activity of Pim-1-3′-UTR was reduced by
~70% in cells expressing miR-486-5p compared with
those expressing the control (Figure 4A). Furthermore,
we generated stable H1299, H157 and A549 cells overex-
pressing miR-486-5p, and measured Pim-1 expression
using Western blot assay. Forced expression of miR-486-
5p in the cells resulted in a decrease of Pim-1 protein
expression compared with control cells (Figure 4B, C).
However, this was not accompanied by a significant re-
duction in mRNA expression in cells overexpressing
miR-486-5p relative to their control cells, respectively
(Figure 4D). Together, miR-486-5p might directly bind to
the 3′-UTR sequences of Pim-1, as well as inhibiting its
expression mainly through posttranscriptional regulation.
We further analyzed miR-486-5p expression in the
same panel of frozen NSCLC tissues that were used for
the analysis of Pim-1 expression. MiR-486-5p was down-
regulated in 87.5% (21of 24) tumor tissues compared
with the matched normal lung tissues (Figure 4E and
Additional file 1: Table S1), whereas Pim-1 protein was
upregulated in 87.5% (21 of 24) tumor tissues by Western
bolt analysis (Figure 1C). The level of miR-486-5p in tu-
mors was significantly lower than that in normal tissues
using Wilcoxon matched pair rank test (Z = −3.971, P <
0.001), which was consistent with our previous report
[20,23]. In addition, in five NSCLC cell lines (A549, H1299,
H157, SK-MES-1 and H358) that showed decreased
Figure 2 (See legend on next page.)
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Figure 2 Effects of Pim-1 on cell growth and cell cycle progression in NSCLC cells in vitro. (A) A549 and H1299 cells were transfected with
Pim-1 siRNA at a final concentration of 50nM. Pim-1 expression was detected using qRT-PCR (Top) and Western blot (Bottom) at 48 h posttransfection.
(B) A549 and H1299 cells were transfected as in (A). In the indicated time periods (0-96 h) posttransfection, cell viability was evaluated using MTT assay.
(C) Cells were stained using propidium iodide (PI) 48 h posttransfection and the cell cycle distribution was analyzed by FACS. (D) CyclinD1 and CDK4
protein expressions were detected in A549 and H1299 cells after transfection with si-Pim-1 by Western Blot assay. All data were obtained from three
independent experiments and shown as mean ± SD and *P <0.05.
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lung tissue (Figure 4F), Pim-1 protein expressions were
all indicated at relatively higher level (Figure 4G and
Additional file 3: Figure S2). Overall, the findings indicated
that miR-486-5p negatively regulated Pim-1 expression at
posttranscriptional level, and the downregulated miR-486-
5p in NSCLC conferred to Pim-1 upregulation by relieving
the inhibitory effect of the 3′-UTR.
Pim-1 expression is controlled by eIF4E at translational
level, and is positively associated with eIF4E expression in
NSCLC cells
To explore the effects of eIF4E on the regulation of
Pim-1 expression and tumorigenesis of NSCLC, we
knocked down eIF4E expression by siRNA and deter-
mined its impact on Pim-1 expression. The basal levels
of eIF4E protein were all abundant in NSCLC cell line
H1299, A549, H157, H460 and H358. Knockdown of
eIF4E was confirmed in A549 (Figure 5A and C) and
H1299 (Figure 5B and D) cells by qRT-PCR and Western
blot analysis. In comparison with control cells, reduced
levels of Pim-1 protein were detected in si-eIF4E trans-
fected A549 (Figure 5C) and H1299 cells (Figure 5D).
However, there was no change on Pim-1 mRNA ex-
pression after si-eIF4E transfection in both of the cells
(Figure 5A and B). The results suggest that eIF4E expres-
sion controls the synthesis of Pim-1 protein in NSCLC
cells. In addition, we found that silencing of eIF4E inhib-
ited cell growth (Figure 5E) and the migratory ability of
the NSCLC cells (Figure 5F). The observation is consistent
with the roles of Pim-1 in NSCLC cells.
We further examined eIF4E expression and deter-
mined the relationship between eIF4E and Pim-1 expres-
sion in 69 human NSCLC specimens. Positive staining
for eIF4E was found in the cytoplasm of the tumor cells
(Figure 5G). EIF4E staining was found in 56 of 69
NSCLCs (81.1%), occurred 37 of 41 adenocarcinoma
(90.2%), 16 of 23 squamous cell carcinoma (69.6%) and 3
of 5 other types (60.0%). As shown in Table 2, eIF4E
expression was significantly associated with tumor diam-
eter (P = 0.036). However, there were no significant asso-
ciations between eIF4E expression and other important
clinicopathological features, such as histological type,
lymph node metastasis, and clinical staging in NSCLC
patients (all P > 0.05, Table 2). Moreover, the correlation
between the expressions of eIF4E and Pim-1 was exploredusing the Spearman’s rank test. 62.3% (43/69) of tumors
positive on eIF4E were also Pim-1 positive, and 15.9% (11/
69) eIF4E negative tumors were Pim-1 negative (Table 3).
There was a positive correlation between eIF4E and Pim-1
expressions in the specimens (r = 0.504, P < 0.001). There-
fore, eIF4E expression is positively associated with Pim-1,
and elevated eIF4E expression could contribute to Pim-1
protein expression in NSCLC.
Pim-1 Knockdown increases the sensitivity of NSCLC cells
to gefitinib and cisplatin
Because Pim-1 has a critical role in NSCLC cell survival,
we hypothesize that knockdown Pim-1 expression can
sensitize NSCLC cells to therapeutic agents. To validate
the hypothesis, cell survival rates were detected in A549,
H157 and H1299 NSCLC cells transfected with control
siRNA or si-Pim-1 combined with drug treatment using
MTT assays. In A549 cells, the viability of cells was de-
creased significantly upon si-Pim-1(~16%, P = 0.031) or
gefitinib (~28%, P = 0.002) treatment alone compared to
the control cells. More importantly, silencing Pim-1 in
combination with gefitinib reduced the viability of A549
cells by about 50% (P = 0.0001, Figure 6A). Similar syner-
gistic effects were also obtained in combination of si-
Pim-1 with gefitinib both in H157 (~80%) and H1299
cells (~60%) compared with their control cells (Figure 6A
and Additional file 4: Figure S3A). The data would sug-
gest that Pim-1 inhibition could improve the effect of
gefitinib clinically. Moreover, Pim-1 knockdown caused
increased susceptibility to cisplatin in A549, H157 and
H1299 cells when compared with the control cells
(Figure 6B and Additional file 4: Figure S3B). Collect-
ively, loss of Pim-1 sensitized NSCLC cells to the che-
motherapeutic drugs.
Discussion
We found that Pim-1 protein was frequently upregulated
in lung tumor tissues, and its expression was closely
related to advanced stage and lymph node metastasis of
NSCLC. Furthermore, reduced Pim-1 expression sup-
pressed NSCLC cell proliferation, cell cycle progression
and migration in vitro. In addition, Pim-1 expression
was negatively regulated by miR-486-5p at posttranscrip-
tional level, whereas positively regulated by eIF4E at
translational level. Moreover, siRNA-mediated Pim-1
knockdown significantly increased the efficacy of EGFR
Figure 3 Effects of Pim-1 on migration of NSCLC cells in vitro. (A) A549 and H1299 cells were transfected with Pim-1 siRNA at a final
concentration of 50nM. The ability of cell motility was evaluated in A549 and H1299 cells after transfection with si-Pim-1 for 48 h using wound
scratch assay. A uniform scratch was made in each confluent layer culture, the extent of wound closure was monitored under microscope, and
photographs were taken at 0 and 48 h. (B) Knockdown of Pim-1 reduces A549 cell migration in the “Transwell assay”. Cells that migrated to the
bottom chamber containing serum-supplemented medium were stained with crystal violet, visualized under microscope, and photographed at
24 h and 48 h, respectively. (C) Average number of cells migrated to the bottom chamber in five fields was counted manually. Data are shown as
mean ± SD. Similar results were obtained in three independent experiments. *P < 0.05.
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tin in NSCLC cells. Therefore, Pim-1 is a critical survival
protein contributed to tumorgenesis and progression of
lung cancer.
Pim-1 belongs to a family of naturally active serine/
threonine kinases. Its activity is dependent on the
amount of protein present in a given cell [27]. In this
study, immunohistochemical results showed that Pim-1
expression was significantly elevated in human NSCLCs,
and was closely related to lymph node metastasis andclinical stage of patients. Our observation was in agree-
ment with the observation by Jin et al. using immuno-
histochemical method [15]. Furthermore, our western
blot results demonstrated that increased Pim-1 protein
level exited in lung tumors and NSCLC cell lines. How-
ever, the level of Pim-1 mRNA did not show significant
difference between tumor and normal tissues. The dis-
crepancies in mRNA and protein expression levels of the
gene suggested that Pim-1 expression might be highly
controlled by some mechanisms at posttranscriptional
Figure 4 (See legend on next page.)
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Figure 4 MiR-486-5p regulates Pim-1 expression at posttranscriptional level. (A) Luciferase activity controlled by Pim-1-3′-UTR was inhibited
by miR-486-5p. A549 cells were co-transfected with firefly luciferase-3′-UTR (pGL3 or pGL3-Pim-1-3′UTR) and pRL-TK vector (as internal control)
along with miR-486-5p or control miR. After 48 h, firefly luciferase and Renilla luciferase were measured. (B) Stable cell lines expressing miR-486-5p or
the vector were selected with puromycin and used for the following experiment. (C) Pim-1 protein was determined in A549,H1299 and H157 cells
stable expressing miR-486-5p by Western Blot assay. (D) The level of Pim-1 mRNA was determined in A549,H1299 and H157 cells stable expressing
miR-486-5p by qRT-PCR assay. (E) miR-486-5p is frequently down-regulated in tumor tissue than the matched normal tissue from the same 24 cases of
human primary NSCLC as mentioned in Figure 1C. (F) miR-486-5p expressions were detected in NSCLC cell lines A549, H1299, H157, SK-MES-1 and
H358 using real-time qRT-PCR. (G) Pim-1 protein expressions in the five NSCLC cell lines were detected by Western Blot assay.
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lated by miRNA and eukaryotic translation initiation
factor 4E at posttranscriptional and translational level,
respectively.
Data from ours [20,21,23] and others [28,29] have in-
dicated that reduced miR-486-5p expression is one of
the most frequent molecular events in NSCLC. There-
fore identifying and characterizing molecular targets of
miR-486-5p will help deep understanding mechanisms
underlying the development and progression of NSCLC.
In the present study, we demonstrated that Pim-1 might
be a novel target of miR-486-5p. Our study suggests
a novel functionality of miR-486-5p in the context of
Pim-1 inhibition at posttranscriptional level. Downregu-
lation of miR-486-5p could contribute to Pim-1 upregula-
tion, and hence promote the development and progression
of NSCLC.
Availability of the eIF4E factor is especially important
for mRNAs with long and structured 5′UTRs. These in-
clude, in particular, short-lived cell cycle regulators and
oncoproteins, like c-MYC, Cyclin D1, BCL2 and MCL1
[24]. Cancer cells require continuous expression of these
proteins, which may provide a therapeutic window for
inhibitors of cap dependent translation in cancer. Li
et al. recently reported that elevated eIF4E expression
promoted proliferation and invasion of NSCLC cells,
and contributed to development of acquired resistance
to EGFR-TKIs [30]. It was reported that Pim-1 kinase is
regulated by eIF4E at the translational level in NIH-3 T3
cells [26]. However, the relationship between eIF4E and
Pim-1 in NSCLC has not been explored. In this present
study, we demonstrated that eIF4E expression was ele-
vated in NSCLCs, and was positively associated with that
of Pim-1 in lung tumor specimens. Furthermore, inhib-
ition of eIF4E expression could decrease Pim-1 protein
expression in NSCLC cells. Therefore, Pim-1 expression
might be regulated by miR-486-5p negatively at post-
transcriptional level, whereas by eIF4E positively at
translational level. Furthermore, the downregulated miR-
486-5p and upregulated eIF4E in lung tumor could lead
to the overexpression of Pim-1 protein by relieving the
inhibitory effects of the 3′-UTR or 5′-UTR of Pim-1
mRNA, respectively.Our in vitro experiments demonstrated that knockdown
of Pim-1 could induce G0/G1 phase arrest of NSCLC cells.
The induced G0/G1 phase arrest was accompanied by the
decreased expression of Cyclin D1 and CDK4 proteins,
which are necessary for G1-S transition. Furthermore,
decreased Pim-1 expression inhibited the cell growth sig-
nificantly. However, Pim-1 knockdown did not affect the
apoptosis of NSCLC cells in our study (data not shown).
These observations supported that Pim-1 might be essen-
tial for cell growth mainly through regulating G1-S cell
cycle progression. Taken together, Pim-1 could have onco-
genic effects and play a key role in cell survival of NSCLC.
Pim-1 has been suggested as an attractive therapeutic
target for different types of cancers. For instance, SGI-
1776, a Pim-1 kinase inhibitor, has been tested in a
pediatric preclinical testing program for leukemia [31].
This Pim-1 kinase inhibitor has the potential to improve
the efficacy of radiotherapy in NSCLC cells [32] and
sensitize prostate cancer cells to gefitinib [12]. Here we
found that siRNA-mediated Pim-1 knockdown increased
the sensitivity of NSCLC cells to cisplatin. Furthermore,
EGFR signaling was recently suggested to couple to acti-
vation of cap-dependent translation in EGFR wild-type
NSCLC cells [33]. Resistance to EGFR-TKI can be medi-
ated through multiple signaling pathways converging
upon cap-dependent translation in EGFR-wild type
NSCLC. Using an antisense oligonucleotide against eIF4E
to disrupt cap-dependent translation can enhance sen-
sitivity to erlotinib [33]. Interestingly, our present study
showed that Pim-1 was involved in the efficacy of EGFR
targeted therapies in NSCLC cells with wild-type EGFR.
Therefore, as a cap-dependent translation protein, Pim-1
mediated drug resistance may relate to the elevated level
of eIF4E in these cells. Future investigation of the molecu-
lar mechanisms of Pim-1 mediated drug resistance would
help develop novel Pim-1-based therapeutic agents to im-
prove the treatment of NSCLC.
Conclusions
Pim-1 kinase could be a critical survival signaling factor
in NSCLC, and regulated by miR-486-5p and eIF4E.
Pim-1 kinase may provide a potential target for diagnosis
and treatment for lung cancer.
Figure 5 (See legend on next page.)
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Figure 5 Elevated eIF4E expression controls the synthesis of Pim-1 in NSCLC. H1299 and A549 cells were transfected with eIF4E siRNA at a
final concentration of 50nM. EIF4E and Pim-1 mRNAs were detected in H1299 (A) and A549 cells (B) using qRT-PCR 48 h posttransfection. Pim-1
and eIF4E protein expression was detected in H1299 (C) and A549 cells (D) using Western Blot assay 48 h psottransfection. (E) Cell growth was
evaluated in A549 and H1299 cells after transfection with si-eIF4E for 0-96 h using MTT assay. (F) The ability of cell motility was evaluated in A549
and H1299 cells after transfection with si-eIF4E for 48 h using wound scratch assay. A uniform scratch was made in each confluent layer culture,
the extent of wound closure was monitored under microscope, and photographs were taken at 0 and 48 h. Data are shown as mean ± SD. Similar
results were obtained in three independent experiments. *P < 0.05. (G) EIF4E expression is frequently elevated in squamous cell carcinoma (a: SP, 100×;
b: a segment magnified at 200×) and adenocarcinoma of lung by immunohistochemistry analysis (c: SP, 100×; d: a segment magnified at 200×).
Pang et al. Molecular Cancer 2014, 13:240 Page 11 of 15
http://www.molecular-cancer.com/content/13/1/240Methods
Patients and clinical specimens
The study protocol was approved by the Institutional
Review Boards of Tumor Hospital of Hebei Medical
University. FFPE sections of lung tumor of 77 NSCLC
patients were collected. Clinical characteristics of the pa-
tients are shown in Table 1. The 77 NSCLC patients
consist of 24 females and 53 males, ages 27 to 72 years
(median, 59 years). Forty-four patients were diagnosed
with adenocarcinoma, 28 with squamous cell carcinoma,Table 2 Clinicopathologic characteristics of the NSCLC






All cases 69 56 13
Age (y) 0.630
<=60 36 30 6
>60 33 26 7
Gender
Male 47 36 11 0.200
Female 22 20 2
Histology 0.058
Squamous cell carcinoma 23 16 7
Adenocarcinoma 41 37 4
Other types 5 3 2
Tumor size 0.036
<=3 cm 35 25 10
>3 cm 34 31 3
Lymphnodemetastasis 0.338
Negative 29 22 7
Positive 40 34 6
Metastasis
No 44 35 9 0.893
Yes 25 21 4
Stage
I 20 15 5 0.629
II 16 14 2
III-IV 33 27 6
NOTE: P values <0.05 were considered statistically significant.and 5 with other subtypes of NSCLC. Twenty-three pa-
tients had stage I disease, 18 patients had stage II disease,
10 patients had stage III disease, and 26 patients had stage
IV. Furthermore, the frozen surgical tumor and corre-
sponding normal lung tissues of 24 patients with NSCLC
were also obtained. In each patient (#1 ~ #24), the tumor
tissues and the normal lung tissues were collected from
the same patient and the diagnosis of each frozen tissues
was confirmed by hematoxylin-eosin staining. Among the
24 patients, 16 were diagnosed with adenocarcinoma
and 8 with squamous cell carcinoma. Twelve patients had
stage I and II disease, 12 patients had stage III and IV dis-
ease. All variants, including age, sex, stage, and lymph
node metastasis, were obtained from clinical and patho-
logic records. None of the patients had received preopera-
tive adjuvant chemotherapy or radiotherapy.
Cell culture
A549, H1299, H358, H157 and SK-MES-1 human lung
cancer cell lines were obtained from Cell Resource Cen-
ter of Peking union Medical College and Cell Bank of
Chinese Academy of Sciences. A549, H1299, H358 and
H157 cells were maintained in RPMI-1640 medium con-
taining 10% fetal bovine serum and penicillin/strepto-
mycin. SK-MES-1 cells were maintained in MEM medium
supplemented with 10% fetal bovine serum and penicillin/
streptomycin. Cultures were maintained in a 5% CO2 hu-
midified atmosphere at 37°C.
Reagents and antibodies
Gefitinib was from Selleck Chemicals (Houston, TX, USA).
Cisplatin was from Sigma-Aldrich Corporation. Antibodies
specific to Pim-1 was from Epitomics (Hangzhou, China).




eIF4E expression (n) Total
Positive Negative
Positive 43 2 45
Negative 13 11 24
Total 56 13 69
(The association between the expression of eIF4E and Pim-1 in NSCLC was
statistically significant (r = 0.504, p = 0.000).
Figure 6 Pim-1 Knockdown increased the sensitivity of NSCLC cells to gefitinib and cisplatin. A549 and H157 cells were transfected with
negative control or Pim-1 siRNA for 24 h and then exposed to 10 μM Gefitinib for 24 h (A), 20 μM cisplatin for 48 h (B), respectively. After the
aforementioned treatments, cell viability was assessed by MTT assays. The data are means ± SDs of four replicate determinations. All data were
obtained from three independent experiments and shown as mean ± s.d. and *P < 0.05 compared with each treatment alone.
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actin was from Santa Cruz Biotechnologies (Santa Cruz,
CA, USA). Pim-1 siRNA and eIF4E siRNA for in vitro
experiment was from Genephma (Shanghai, China). MiR-
486-5p expressing vector and the negative control vector
were from Genecopoeia Co. (Guangzhou, China).
RNA extraction, reverse transcription, and real-time RT-PCR
Total RNA from frozen tissues and cultured cells was
extracted using TRIzol reagent (Life TechnologiesCorporation, Carlsbad, CA, USA). To detect Pim-1 and
eIF4E mRNA expression, first-strand cDNA was first
synthesized from 1 μg RNA using SuperScript II reverse
transcriptase (Invitrogen), followed by PCR amplification
using 5% cDNA for each reaction. The sequences of the
primers were as follows: Pim-1 forward, 5′-TCATTAG
ATGGTGCTTGGCCCTGA-3′; Pim-1 reverse, 5′-TGT
GGA GGTGGATCTCAGCAGTTT-3′; eIF4E forward,
5′-CAGAGACGAAGTGACC TCAATC-3′; eIF4E re-
verse, 5′-CATTAACAACAGCGCCACATAC-3′; β-actin
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reverse, 5′-GGGCACGA AGGCTCATCATT-3′. β-actin
was used as an internal control. For miR-486-5p expres-
sion, cDNA was synthesized from total RNA with spe-
cific stem-loop primers and the TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems; Foster
City, CA). Expression of miRNAs was analyzed by real-
time PCR using the TaqMan MicroRNA Assay kit (Ap-
plied Biosystems; Foster City, CA) as described in our
previous study [23]. U6 small nuclear RNA was used as
an internal control. Experiments were repeated at least
three times.
siRNA silencing of Pim-1 or eIF4E
Transfections were performed using Lipofectamine 2000
reagent (Invitrogen, Grand Island, NY) following the
manufacturer’s protocol. Cells were transfected with 50
nM Pim-1 siRNA (Genephma, Shanghai, China) or their
relative control sequences, and the cells were harvested
48 hours after transfection. Sequence of siRNA targeting
Pim-1 is 5′-CCUUCGAAGAAAUCCAGAATT-3′. Se-
quence of siRNA targeting eIF4E is 5′-GGACGAUGGC
UAAUUACAU-3′. Sequence of negative control siRNA is
5′-UUCUCCGAACGUGUCACGU-3′. At least three in-
dependent experiments were carried out.
Stably enforcing expression of miR-486-5p in NSCLC cells
To force expression of miR-486-5p in NSCLC cells, cells
were transfected with miR-486-5p expressing vector
(clone number: HmiR0130-MR04) or the empty vector
(clone number: CmiR0001-MR04) (Genecopoeia Co.,
Guangzhou, China) by using Lipofectamine 2000 ac-
cording to the manufacturer’s instructions. 48 h after
transfection, cells were selected with 2 μg/ml puromycin
to obtain the miR-486-5p expressing clones.
Bioinformatics
The software programs miRecords (http://mirecords.
biolead.org/) was used to predict the potential target
genes of miR-486-5p.
Pim-1 gene 3′ untranslated region (UTR) luciferase
reporter assay
To create 3′-UTR luciferase reporter construct of Pim-
1, 1200-bp sequences from putative miR-486-5p binding
sites were synthesized and cloned into the pGL3-RE-
PORT vector (Promega, Shanghai, China). The following
primers were used to amplify the 3′-UTR of Pim-1: 5′-
CCGACGCGTCAACATTTACAACTCATTCCA G-3′
and 5′-CCGCTCGAGTTTATTCAAAAAACGCCAAGT-
3′. The amplified fragment was cloned into pGL3 lucifer-
ase report vector at Mlu I and Xho I sites. The sequence
of plasmid (pGL3-Pim-1) was confirmed by DNA sequen-
cing. Luciferase reporter assay was performed accordingto the previously described method [23,34]. Briefly, cancer
cells (5 × 104 per well) were seeded in a 24-well plate the
day before transfection, and then co-transfected with fire-
fly luciferase-3′-UTR (pGL3 or pGL3-Pim-1, 500 ng) and
pRL-TK vector (Promega) along with miR-486-5p mimics
or control (Ribobio Co. Guangzhou, china). After two
days, firefly luciferase and Renilla luciferase were mea-
sured by using synergy™ HT microplate reader (Biotek,
Beijing, China) with the Dual-Glo® Luciferase assay system
(Promega). Luciferase activities were normalized to Renilla
luciferase activity. Experiments were repeated at least
three times.
MTT assay
Cells (4 × 103 cells) were seeded onto 96-well plates in
normal culture condition overnight followed by siRNA
transfection specific for Pim-1 or eIF4E, and the cells
viability was assessed in four replicates at 24, 48, 72 and
96 h after transfection. For drug treatment, cells with
si-Pim-1 transfection were plated in 96-well plates for
24 h, and then gefitinib or cisplatin was added to the
cultures. The cells viability was assessed at 24 or 48 h
after the drug treatment. The experiments were per-
formed at least three times.
Colony formation assay
For colony formation assays, after 24-hour posttransfec-
tion, the cells were diluted and replated in six well
plates. After ten days, visible colonies were fixed with
methanol, stained with crystal violet, counted, and nor-
malized to control group. The experiments were per-
formed at least three times.
Cell cycle analysis
Cells were collected and washed twice with cold PBS.
For cell cycle analysis, cells were fixed in 70% ethanol at 4°
C overnight. After centrifugating for 5 min at 1, 000 rpm
at 4°C, the pellet was treated with 2 mg/ml RNase A at
37°C for 20 min and stained with 50 μg/ml propidium
iodide (PI) containing 0.1% Triton X-100 and EDTA
0.02 mg/ml. Cell suspensions were analyzed by Flow Cy-
tometry on a FACS Calibur system (BD Biosciences,
Heidelberg, Germany). Cell cycle distribution were counted
using Muticycle AV software. All measurements were per-
formed in duplicate.
Wound-healing assay
To determine cell migration, cells were seeded in 6-well
plates and incubated to generate confluent cultures.
Wounds were scratched in the cell monolayer using a 200
micropipette tip. The cells were rinsed with phosphate-
buffered saline (PBS). The migration of the cells at the
edge of the scratch was monitored at 48 h. The cells were
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experiments were carried out.
Transwell assay
Cells were plated in medium without serum in the top
chamber of a transwell (Corning, NY). The bottom cham-
ber contained standard medium with 10% FBS. After incu-
bation for 24 h or 48 h, the cells that had migrated to
the lower surface of the membrane were fixed with forma-
lin, stained with crystal violet, and photographed under
microscope. Cell numbers were counted under a light
microscope at X400 magnification. Experiments were car-
ried out at least three times.
Western blot
Total proteins (50-100 μg) extracted from cell lines or
human NSCLC and adjacent normal tissues were analyzed
by SDS-polyacrylamid gel electrophoresis and were trans-
ferred electrophoretically to nitrocellulose membrane. To
evaluate expression of the proteins, blots were blocked
with 5% nonfat milk in Tris-Buffered Saline and Tween
20, and incubated with a primary rabbit monoclonal anti-
body Pim-1, Cyclin D1, CDK4 or eIF4E. Antibody for β-
actin (Santa Cruz Biotechnology, Santa Cruz, CA) was
used as a control. The blots were then re-probed with sec-
ondary antibody and visualized by the chemiluminescence
and scanned using ImageQuant LAS 4010 Imaging System
(GE Healthcare Life Sciences, Piscataway, NJ).
Immunohistochemistry assay
Immunohistochemistry staining was done on 77 FFPEs
using rabbit monoclonal antibody against human Pim-1
(Epitomics). EIF4E expression was detected on 69 avail-
able FFPEs out of the 77 cases using rabbit monoclonal
antibody against human eIF4E (Cell signaling Technology,
Danvers, MA). All sections were examined and scored in-
dependently by two investigators without any knowledge
of the clinicopathological data of the patients. The degree
of immunostaining was evaluated by the proportion of
positive staining tumor cells and the staining intensities.
Scores representing the proportion of positively stained
tumor cells were graded as: 0 (no positive tumor cells); 1
(<10%); 2 (10%–50%); and 3 (>50%). The intensity of stain-
ing was determined as: 0 (no staining); 1 (weak staining =
light yellow); 2 (moderate staining = yellow brown); and 3
(strong staining = brown). The staining index (SI) was cal-
culated as the product of staining intensity × percentage
of positive tumor cells. SI score of greater than 1 was con-
sidered to be positive staining.
Statistical analysis
Data are presented as mean ± SD. Statistical comparisons
between experimental groups were analyzed by t test.
Spearman’s correlation analysis was used to determinecorrelation between Pim-1, eIF4E expression level, and
clinical characteristics of the NSCLC patients. Wilcoxon
matched pair rank test was used to analyze Pim-1 and
miR-486-5p expression level between tumor tissues and
paired adjacent normal lung tissues. P < 0.05 was taken to
indicate statistical significance.
Additional files
Additional file 1: Table S1. The relatively expression of miR-486-5p and
Pim-1 protein in 24 cases of human primary NSCLC normalized to the
paired normal lung tissues.
Additional file 2: Figure S1. The effects of si-Pim-1 on cell proliferation
in A549 cell in vitro. A549 cells were transfected with Pim-1 siRNA at a
final concentration of 50nM. Cell proliferation was determined by clone
formation assay. 500 cells were replated in six well plates after 24-hour
posttransfection. After ten days culture, visible colonies were fixed with
methanol, stained with crystal violet. The experiments were performed at
least three times.
Additional file 3: Figure S2. Pim-1 protein expressions were
overexpressed in NSCLC cell lines (A549, H1299, H157, SK-MES-1 and
H358) compared to the average level of Pim-1 in normal lung tissues by
Western Blot assay. The level of Pim-1 protein in 24 cases of human
normal lung tissue was used as negative control, and the relatively
expression of Pim-1 protein in cell lines was normalized to the normal
lung tissues.
Additional file 4: Figure S3. Pim-1 Knockdown increased the sensitivity
of H1299 cells to gefitinib and cisplatin. H1299 cells were transfected
with negtive control or Pim-1 siRNA for 24 h and then exposed to 20 μM
gefitinib for 24 h (A) or 20 μM cisplatin for 48 h (B) respectively. After the
aforementioned treatments, cell viability was assessed by MTT assays. All
data were obtained from three independent experiments and shown as
mean ± s.d. #P < 0.05 compared with each treatment alone.
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